All In Biotech

Drug Trial Radar · NCT06006247

Early Parkinson's Disease Monotherapy With CVN424

A Randomized, Double-Blind, Placebo-Controlled Trial of CVN424 in Early Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

64

Actual

Start

Sep 11, 2023

Primary completion

Jan 30, 2025

Study completion Feb 13, 2025

Sponsor

Lead sponsor
Cerevance Beta, Inc.Industry
Sponsor type
Industry
First posted
Aug 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not taking dopaminergic or anti-PD therapies.

Conditions

  • Parkinson's Disease

Interventions

  • CVN424 150 mgDrug

    Participants will receive 1 CVN424 tablet (150 mg) per day.

  • PlaceboDrug

    Participants will receive 1 matching placebo tablet per day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 12 on the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II + Part IIITime frame: Baseline (Day 1) and Up to Week 12

Locations

42 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Barrow Neurological Institute

    Phoenix, Arizona

  • St Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • Muhammad Ali Parkinson Center

    Phoenix, Arizona

  • Movement Disorders Center of Arizona, LLC

    Scottsdale, Arizona

  • Parkinson's Research Centers of America - Palo Alto

    Palo Alto, California

  • CenExel Rocky Mountain Clinical Research

    Englewood, Colorado

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida

  • SFM Clinical Research, LLC

    Boca Raton, Florida

  • N1 Research LLC

    Orlando, Florida

  • Parkinson's Disease Treatment Center of SWFL

    Port Charlotte, Florida

  • University of South Florida Parkinson's Disease and Movement Disorders Center

    Tampa, Florida

  • Augusta University

    Augusta, Georgia

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Kentucky, Dept of Neurology Kentucky Neuroscience Institute Research

    Lexington, Kentucky

  • University of Kentucky, Center for Clinical and Translational Sciences

    Lexington, Kentucky

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • University of Michigan Hospital / Michigan Clinical Research Unit (MCRU) Cardiovascular Center

    Ann Arbor, Michigan

  • University of Michigan Department of Neurology

    Ann Arbor, Michigan

  • Quest Research Institute

    Farmington Hills, Michigan

  • Struthers Parkinson's Center

    Golden Valley, Minnesota

  • Albany Medical Center

    Albany, New York

  • Parkinson's Research Centers of America - Long Island

    Commack, New York

  • Weill Cornell Medicine

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Riverhills Healthcare, Inc dba Riverhills Neuroscience

    Cincinnati, Ohio

  • The Ohio State University Department of Neurology - Madden Center for Parkinson Disease and Other Movement Disorders

    Columbus, Ohio

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Martha Morehouse Medical Plaza

    Columbus, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Veracity Neuroscience

    Memphis, Tennessee

  • Horizon Clinical Research Group

    Cypress, Texas

  • Texas Movement Disorder Specialists, PLLC

    Georgetown, Texas

  • Gill Neuroscience

    Houston, Texas

  • Central Texas Neurology Consultants

    Round Rock, Texas

  • Inova Neurology - Fairfax

    Fairfax, Virginia

  • Inova Fairfax Medical Campus

    Falls Church, Virginia

  • EvergreenHealth Neuroscience Institute

    Kirkland, Washington

  • EvergreenHealth Research Department

    Kirkland, Washington

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.